FindTrial
Sign In

The molecular mechanism of LncRNA GAS5 in the regulation of progression of diabetes with endometrial carcinoma

The molecular mechanism of LncRNA GAS5 in the regulation of progression of diabetes with endometrial carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015657
Enrollment
Unknown
Registered
2018-04-13
Start date
2018-04-18
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial carcinoma

Interventions

Endometrial carcinoma group:Nil
Endometrial carcinoma with diabetes group:Nil

Sponsors

Metabolic disease Hospital, Tianjinf Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
31 Years to 65 Years

Inclusion criteria

Inclusion criteria: Specimens were collected from two groups patients, endometrial carcinoma with diabetes, and simple endometrial carcinoma.

Exclusion criteria

Exclusion criteria: endometrial carcinoma with other cancers

Design outcomes

Primary

MeasureTime frame
LncRNA GAS5;—

Contacts

Public ContactZhenjin Li

Metabolic disease Hospital, Tianjinf Medical University

15122181532@139.com+86 15122181532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026